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CASE SERIES

Postablation Endometrial Carcinoma
Morris Wortman, MD, George A. Vilos, MD, Angelos G. Vilos, MD, Basim Abu-Rafea, MD,
Wendy Dwyer, MD, Robert Spitz, MD

ABSTRACT

Key Words: Endometrial ablation complications, Global
endometrial ablation complications, Reoperative hysteroscopic surgery, Late-onset endometrial ablation failure,
Ultrasound-guided reoperative hysteroscopy.

Background: Many women have undergone both resectoscopic and nonresectoscopic (or global) endometrial
ablation (EA) during the past 20 years. These women are
now approaching their sixth and seventh decades of life,
a time frame in which endometrial carcinoma (EC) is most
frequently diagnosed.

INTRODUCTION

Database: In several reports, surgeons have expressed
concern that endometrial ablation may leave a sequestered island of EC that may escape detection, possibly
delaying its diagnosis or causing it to appear at an advanced stage. Others suggest that EA artifact does not
hinder the evaluation and treatment planning in the presence of EC. Data bases used are from Medline and
PubMed.

Endometrial ablation (EA) traces its history to 1898 when
Albert Dührssen1 described the first case of selective endometrial destruction in an attempt to provide relief for a
37-year-old woman “exhausted by profuse and persistent
menorrhagia by introducing steam into the uterine cavity
for 2 minutes.” Dührssen noted that “as a result, the uterus
underwent complete atrophy.”
Following the development of electrosurgical generators
Bardenheuer,2 in 1937, published “Elextrokoagulation
(ELK) der Uterusschleimhaut, (Electrocoagulation of the
endometrium),” by introducing a unipolar electrode (Kungelsondenelktrode) varying from 5 to 8 mm and mounted
on a 12- to 16-cm shaft. In 1948 Bauman3 promoted
Bardenheuer’s technique and reported a series of 387
women who were treated in an office setting under “light
narcosis.” Bardenheuer reported a very low complication
rate, but identified the first cases of late-onset endometrial
ablation (EA) failure and stressed the importance of avoiding electrocoagulation of the internal os, to reduce the
likelihood of hematometra formation and cyclic pelvic
pain.

Discussion: We introduce 6 new cases of postablation
endometrial carcinoma (PAEC), 4 of which occurred after
the introduction of global endometrial ablation (GEA)
techniques. In addition, we examine several key questions regarding the impact of EA on the subsequent development of EC, including the manner in which PAEC
presents, the efficacy of traditional diagnostic modalities,
the ablation-to-cancer interval, and the stage of PAEC at
the time of diagnosis. Finally, we explore the use of
reoperative hysteroscopic surgery (RHS) as a diagnostic
modality and address the possible role ultrasound surveillance as a screening method for women at risk of EC.
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In the early 20th century, after Marie Curie’s discovery, the
use of radium attracted the interest of physicians because
of its ability to affect human tissue. In 1937, Schultze4
reported a series of 204 women with menorrhagia who
were treated with intrauterine radium in hopes of achieving a restoration of normal cyclic menses; unlike today,
amenorrhea was regarded as “overtreatment.” The application of intrauterine radium, however, was fraught with
undesirable side-effects, including atrophic vulvitis, sterility, and dyspareunia, and was soon abandoned.
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The next foray into EA came in 1967 when Cahan and
Brockunier5 reported the first attempts at cryoendometrial
ablation. Droegemueller et al6 described a similar tech-
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lation device (NovaSure EA; Hologic, Inc., Bedford, Massachusetts, USA); and a microwave ablation system (MEA
System; previously produced by Microsulis Medical Limited, Denmead, UK). In 2015, a sixth system using radiofrequency energy and a plasma formation array (PFA) also
became available (Minerva Endometrial Ablation System;
Redwood City, California, USA). These systems, reminiscent of the original “blind” techniques of the early 20th
century, boast 2 important advantages: their operation is
easily learned and they are exceptionally safe. Global EA
(GEA) techniques obviated the risks of fluid overload and
hyponatremia while curtailing the incidence of the visceral injuries once associated with resectoscopic procedures.12,13 These benefits enabled the growth of the U. S.
global GEA market, which in 2012 entailed 390,000 procedures14 valued at $730 million.15 The domestic GEA
market is forecast to reach 490,000 procedures by 2017,14
and, together with resectoscopic endometrial ablation
(REA), may soon surpass the number of hysterectomies in
the United States.16

nique using both Freon (DuPont, Deepwater, New Jersey,
USA) and nitrous oxide probes. Despite some success,
these devices proved to be costly and cumbersome and
were abandoned because of the potential for producing
painful hematometra.
A paradigm shift occurred when Goldrath et al7 colocated
the rod–lens system of a hysteroscope with a Neodymium:
YAG (Nd:YAG) laser and, in 1981, reported the first cases
of EA under direct visualization. Despite their success, the
use of the Nd:YAG for EA never gained wide acceptance
for at least 3 reasons. First, most gynecologists were unfamiliar with hysteroscopy. Second, the cost of a typical
Nd:YAG laser in the mid-1980s— over $100,000 U.S.—was
prohibitively expensive. Third, the continuous-flow hysteroscope had not yet been invented, and the laser procedure posed many operative challenges.
Several years later, however, DeCherney and Polan8 used
a conventional urologic resectoscope to perform EA. Because DeCherney’s energy source—an inexpensive monopolar electrosurgical unit—was already available in
most operating rooms, one significant problem confronting hysteroscopic EA had been addressed. However, the
lack of a continuous flow resectoscope limited the acceptance of DeCherney’s technique.

The use of GEA devices is a major factor in the sharp
decline in the incidence of immediate postablation complications, but there have been several reports of lateonset EA failures (LOEAFs)17–20 in the months and years
after EA. Longinotti et al19 and Munro20 both noted that
late-onset EA complications cause 25% of women to require hysterectomy within 5 years after undergoing EA.
LOEAFs have thus far presented in 3 separate ways: persistent or recurrent vaginal bleeding,17–20 the development
of cyclic pain,17–20 and the inability to adequately assess
the endometrium in women who would later require its
evaluation.21

In 1989, the U. S. Food and Drug Administration (FDA)
approved the continuous-flow gynecologic resectoscope
and Vancaillie9 reported the first cases of EA with a ballend electrode. The inexpensive acquisition costs and excellent visualization allowed this technique to gain some
limited popularity within the gynecologic community. Although resectoscopic EA had its adherents, early reports
of fatalities resulting from uterine perforation, visceral
injury, and distention fluid overload were of great concern
to surgeons. In 1993 Arieff and Ayus10 and Baggish et al11
separately reported a series of deaths attributed to hyponatremic encephalopathy, and the search for safer EA
methods ensued.

The concern regarding adequate endometrial assessment
was first expressed by DeCherney et al,22 who in 1987
forewarned that the consequence of failing to destroy a
“nest of endometrial tissue” could result in a sequestered
island of endometrial carcinoma (EC) inaccessible to standard biopsy techniques, possibly delaying or obscuring
the diagnosis. Subsequently, McCausland and McCausland,23 AlHilli et al,24 and Neuwirth et al25 have echoed
similar concerns.

An important paradigm shift in EA occurred in 1997 with
the introduction of the first nonresectoscopic endometrial
ablation (NREA) or “Global ablation” devices. These are
often collectively called second-generation devices, a
term that belies their history. Between 1997 and 2003, a
total of 5 NREA devices received FDA approval: the thermal balloon (ThermaChoice Uterine Balloon System;
Johnson and Johnson, New Brunswick, New Jersey, USA);
the cryoablation system (Her Option; Cooper Surgical,
Trumbull, Connecticut, USA); a heated free-fluid system
(Hydro ThermAblator or HTA System; Boston Scientific,
Natick, Massachusetts, USA); a bipolar radiofrequency abApril-June 2017 Volume 21 Issue 2 e2017.00011

Meanwhile, in the 3 decades since DeCherney’s initial
concerns, both EA and EC have evolved in the United
States and other developed countries. Hologic Inc., the
manufacturer of the most commonly employed GEA device,14,18 reported that more than 2 million NovaSure procedures were performed between 2001 and 2014.26,27
Concomitantly, the United States and many other countries are experiencing a significant increase in the preva2
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lence of EC,28 –32 largely attributable to an aging and increasingly obese population. The changing landscape of
EC and the widespread adoption of EA will present looming challenges as our specialty faces a large cohort of
women who have undergone EA and are about to enter
their sixth and seventh decades of life—peak years for the
presentation of EC.

[AP] thickness, and 8.5 cm transverse) that contained an
apparent septum, along with evidence of “endometrial
thickening” in both cornual regions; a complex and multiseptated left ovarian cyst (6.4 ⫻ 4.8 ⫻ 8.1 cm) was also
identified. A CA-125 drawn at the time of this evaluation
was 40.8 (normal, ⬍30). Several days later, the patient
experienced an episode of vaginal bleeding accompanied
by severe relapsing and remitting left lower quadrant and
suprapubic pain.

In 2011, AlHilli et al24 reviewed the English literature and
reported 17 cases of postablation EC. One of the authors
(MW), has since reported an 18th subject in a previous
paper.32 This paper will present 6 additional occurrences
of PAEC and summarize our current understanding of this
entity. The authors will attempt to address 4 important
questions: First, how has the widespread adoption of EA
affected the subsequent development of EC? Second, will
PAEC present different symptomatically, compared with
women who have never undergone this procedure? Third,
does a history of EA present diagnostic challenges to the
confirmation of EC? Fourth, do EA-treated women present
at a more advanced stage compared to other women in
the population? Finally, we will offer suggestions for EC
surveillance based on our present but limited knowledge
of PAEC, as a very large group of women who have
undergone EA enter a time frame that places them at
greater risk for developing EC.

The patient was referred to a gynecologic oncologist for
evaluation of her left ovarian mass. On June 19, 2014, she
underwent a robot-assisted left salpingo-oophorectomy
and resection of a retroperitoneal mass, histologically confirmed to be an endometrioma. No attempt was made to
evaluate the uterine cavity. On July 25, 2014, the patient
experienced another episode of left lower quadrant pain
unaccompanied by vaginal bleeding. An ultrasonogram
revealed a prominent area of “endometrium” measuring
16.1 mm in AP thickness in the left fundal portion of the
uterus, along with a 5.6 ⫻ 2.7-cm fluid collection within
the cul-de-sac. There was also a complex right ovarian
cyst that measured 4.6 ⫻ 4.9 ⫻ 3.2 cm with septations and
homogeneous echoes. An endometrial biopsy was attempted on July 29, but the operator failed to gain access
to the uterine cavity.
On August 25 the patient underwent an abdominal hysterectomy requiring extensive adhesiolysis. A frozen section revealed complex hyperplasia; likely atypical. The
final pathology revealed an endometrioid type adenocarcinoma with mucinous and secretory features; FIGO (International Federation of Gynecology and Obstetrics)
grade 1. The carcinoma involved 80% of the “endometrial
surface” but demonstrated no myometrial invasion. Other
histologic features included a background of atypical
complex hyperplasia, adenomyosis, and leiomyomata.
The right ovary contained an endometrioma, and the right
fallopian tube revealed endometriosis with foci of atypical
complex hyperplasia. No further treatment was found to
be necessary, and the patient’s cancer antigen (CA)-125
has since returned to normal.

The University of Rochester Research Subjects Review
Board reviewed the manuscript and deemed that “the
project does not qualify as human subjects research (45
CFR 46.102), in that the activities do not meet the federal
definition of research.”

CASE REPORTS
Case 1
The patient was a 41-year-old woman who presented with
abnormal uterine bleeding (AUB) and underwent an endometrial biopsy that revealed a weakly proliferative endometrium with focal breakdown. Two months later, in
June 2007, she underwent a diagnostic hysteroscopy and
polypectomy immediately followed by a radiofrequency
EA (NovaSure; Hologic Inc.). The histologic examination
revealed a benign endometrial polyp in a background of
proliferative endometrium.

Case 2
In 1994 a 33-year-old woman underwent a roller-ball EA
by one of the authors (GAV). The patient was seen in the
ensuing years for annual examinations and reported excellent results, noting only regular monthly episodes of
light bleeding and spotting.

The patient was seen for annual examinations and did
well for nearly 7 years, until April 22, 2014, when she
presented with left lower quadrant pain unaccompanied
by vaginal bleeding. Ultrasonography revealed a slightly
enlarged uterus (12.2 cm long ⫻ 6.6 cm anterior-posterior
April-June 2017 Volume 21 Issue 2 e2017.00011

Seventeen years later, on September 10, 2011, the patient
presented for evaluation of abnormal perimenopausal
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leiomyomas. There was no evidence of a hematometra,
and no attempt was made to perform a diagnostic hysteroscopy or endometrial biopsy. Instead, the patient was
scheduled for a hysterectomy and bilateral salpingo-oophorectomy. At the time of the laparotomy there was a
solid mass arising from the right ovary that was densely
adherent to the right pelvic sidewall and to the rectosigmoid.

bleeding. An endometrial biopsy was performed and produced “scant endometrial tissue with small, rare fragments
of atypical cells, with cytologic atypia and showing focal
necrosis.” She subsequently underwent a reoperative hysteroscopic surgery (RHS) on January 26, 2012, at which
time the surgeon observed a narrow and distorted uterine
cavity that contained endometrial lining that was described as highly suspicious for endometrial neoplasia.
Her RHS procedure included a lysis of adhesions and total
endomyometrial resection. A subsequent histologic analysis revealed an endometrioid adenocarcinoma, FIGO 3.
On March 22, 2012 she underwent a total laparoscopic
hysterectomy, bilateral salpingo-oophorectomy, and a
pelvic and para-aortic node dissection. The specimen
weighed 103 g and revealed no evidence of residual
endometrial carcinoma in the uterus, tubes, ovaries, and
lymph nodes. At this writing, she was doing well.

The pathologic specimen (115 g, including a 10.0 ⫻ 4.5 ⫻
4.6-cm uterus) contained a mixed EC with 50% described
as undifferentiated and 50% serous. There was a 50%
invasion into the myometrium, deep invasion into the
endocervical stroma, diffuse lymphovascular invasion,
and metastatic disease identified in the right ovary (stage
III). On January 26, 2010, she underwent a right mastectomy for a carcinoma of the breast. At the time of this
report she was alive and well.

Case 3
Case 4

A 56-year-old para 3 patient presented to her primary
gynecologist in 2000 for evaluation of bleeding after
a normal menopause 4 years prior. Her history included a
stage I intraductal carcinoma of the left breast requiring a
mastectomy in 1991. At the time of her presentation, her
BMI was 29 kg/m2, and she was otherwise healthy. The
woman’s primary gynecologist performed a fractional dilation and curettage that revealed “scant inactive endometrium and benign cervical tissue.” Her gynecologist also
noted a bulky uterus, which was attributed to the presence of leiomyomas, and the patient was offered a hysterectomy. The subject, seeking a less invasive approach,
was referred to one of the authors (GAV) for a hysteroscopic evaluation and treatment.

A patient 45-year-old mother of 4 underwent a thermal
balloon EA (ThermaChoice II; Johnson and Johnson, Inc.)
on October 26, 2006. An endometrial curettage performed
just before her procedure revealed proliferative endometrium.
Ten years after surgery, at age 55, she experienced an
episode of postmenopausal bleeding and was referred to
one of the authors (GAV) for management. The patient’s
medical problems included hypertension and hypothyroidism, for which she was taking appropriate medications. Her BMI was 24 kg/m2. On pelvic examination, the
uterus was normal size, mobile, and without adnexal
enlargement. Transvaginal sonography suggested a bicornuate uterus with a 1.4-cm subendometrial leiomyoma
abutting the endometrial surface near the left cornua. The
endometrial thickness varied from 7 to 8 mm. Both ovaries
were identified and described as normal appearing. A
Papanicolaou test revealed atypical glandular cells of endometrial origin.

On January 28, 2000, she underwent a hysteroscopic endomyometrial resection and EA, at which time the uterus
was reported to be quite small and mobile. The cervix was
stenotic but subsequently allowed dilation to 10 mm permitting the introduction of a 26 French continuous-flow
unipolar resectoscope. The endometrium was observed to
be thin and normal appearing. The tubal ostia and fundus
were electrocoagulated with a 5-mm rollerball electrode,
while the rest of the endometrium was resected along
with a small endocervical polyp. A histologic analysis of
the specimen revealed only basalis-type endometrium
and myometrium without significant abnormalities.

An endometrial biopsy was performed and revealed a
well-differentiated endometrioid adenocarcinoma FIGO
grade 1 with mucinous differentiation. The patient underwent a laparoscopic-assisted vaginal hysterectomy and
bilateral salpingo-oophorectomy in August 2016. On histopathologic analysis, the uterus weighed 66.2 g and contained an endometrioid adenocarcinoma variant with mucinous differentiation (FIGO grade 1); there was less than
50% myometrial invasion.

The patient did well and remained amenorrheic until
2005, when she presented with pelvic discomfort and pain
unaccompanied by vaginal bleeding. A transvaginal sonogram revealed a slightly enlarged uterus with multiple
April-June 2017 Volume 21 Issue 2 e2017.00011
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Case 5
The patient, a 42-year-old gravida 3 para 3, underwent an
EA with a glycerine-filled thermal balloon ablation device
(Thermablate EAS; System Indoman Ltd., Toronto, Ontario, Canada) in 2007 for abnormal uterine bleeding. An
endometrial biopsy performed a year before her procedure revealed proliferative endometrium. After her EA the
patient experienced monthly episodes of spotting and
was quite satisfied with the results.
In 2013, however, she began experiencing irregular menses associated with pelvic pain. Ultrasonography performed on December 8, 2014, revealed an enlarged uterus
measuring 13.3 ⫻ 6.2 ⫻ 8.0 cm with an inhomogeneous
myometrium containing a 4.6 ⫻ 4.3-cm area consistent
with adenomyosis. The endometrium was described as
irregular appearing with a thickness of 1.9 mm. On May 8,
2015, her primary gynecologist performed a diagnostic
hysteroscopy and described an irregular uterine cavity
with polypoid endometrium and vascular polyps. An endometrial curettage was performed but the specimen did
not identify any endometrial tissue, and the patient was
subsequently referred to one of the authors (GAV).

Figure 2. Appearance of right cornua after adhesiolysis exposing a well-differentiated adenocarcinoma of the endometrium
along the right posterior surface.

consistent with malignancy. The area was resected in its
entirety, together with a 2-cm leiomyoma. The tissue specimen, measuring 3.4 ⫻ 4 cm, was reported to contain a
well-differentiated endometrioid adenocarcinoma (FIGO
1) in a background of atypical hyperplasia; foci suspicious
for microinvasion were also identified. On January 12,
2016, she underwent a laparotomy, total hysterectomy,
and bilateral salpingo-oophorectomy with peritoneal
washings. The 250-g specimen contained focal residual
endometrioid adenocarcinoma (FIGO 1) at the fundus,
with no evidence of myometrial invasion, and no other
evidence of malignancy. The patient was doing well at the
time of this report.

The patient presented on October 5, 2015. Now, at age 50,
her medical history included sleep apnea, hyperlipidemia,
and impaired glucose tolerance. On November 12, 2015,
she underwent a RHS including endomyometrial resection
and myomectomy. During the procedure a narrow area
was identified just beyond the internal os that opened into
a larger and sequestered cavity (Figures 1, 2) containing
endometrium that was described as thick, polypoid, and

Case 6
A 49-year-old para 2 patient underwent a NovaSure EA on
July 2, 2009. Her preoperative evaluation included transvaginal ultrasonography that revealed an enlarged uterus
measuring 13.7 ⫻ 6.4 ⫻ 9.3 cm and containing 3 leiomyomas varying from 1.3 to 3.1 cm in greatest dimension; an
endometrial biopsy revealed early secretory endometrium. A diagnostic hysteroscopy was not performed at the
time of the NovaSure procedure. The patient enjoyed
excellent results, including light cyclic menses until menopause in 2013. She later admitted to using an over-thecounter progesterone cream for an unspecified period of
time to remedy her menopausal hot flashes and apparently achieved good results.
On April 17, 2015, the patient—now 54 years old—was
seen by her primary gynecologist for an annual examination. She reported some diminished vaginal lubrication

Figure 1. Example of sequestered endometrial cancer after endometrial ablation located at the right cornua. Adhesions obscuring access to the right cornua area.

April-June 2017 Volume 21 Issue 2 e2017.00011
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and was counseled regarding the possible use of estradiol
vaginal cream which she eventually began administering
in October 2015. On March 8, 2016, she reported an
episode of postmenopausal bleeding, discontinued any
further exogenously administered estrogen, and contacted
her gynecologist (RS).

All the patients have provided consent for their cases to be
published.

RESULTS
The mean age of subjects in this series at the time of their
original EA procedure was 44.3 years (95% CI 47.9 –58.0),
and the mean age at the time of their EC diagnosis was
53.6 years (95% CI 47.9 –58.3). The average interval from
EA to the diagnosis of EC was 8.8 years (95% CI 4.2–13.5).
Four of the subjects had undergone a previous GEA procedure, and the remaining 2, a resectoscopic procedure.
Pelvic pain was an important feature in 3 of the women
and the only symptom in 2 of the 6.

A transvaginal ultrasound examination revealed an intramural fundal leiomyoma measuring 3.2 ⫻ 2.6 cm. In
addition, there was a 9 ⫻ 11 mm echogenic area located
within the uterus. The subject underwent a diagnostic
hysteroscopy on April 8, 2016, during which RS reported
entry into the lower uterine segment where dense intrauterine adhesions were identified. A small opening was
detected in the lower uterine segment but was insufficient
to allow the passage of even a 5-mm hysteroscope. A
smaller diameter hysteroscope and biopsy instrument
were eventually passed into the left side of the uterus
permitting selected endometrial biopsies. A histologic
analysis of the specimen revealed a mixed carcinoma
consisting of a low-grade endometrioid adenocarcinoma
and a high-grade carcinoma with neuroendocrine differentiation.

Traditional office-based endometrial biopsy was successfully performed in only one of the subjects (case 4) and
was never attempted in another subject (case 3). An endometrial biopsy attempt in patient 1 failed. In patients 2
and 5, a reoperative hysteroscopic technique with a resectoscope was used, while a small diameter hysteroscope was necessary to gain access to a sequestered area
of endometrium to establish the diagnosis in patient 6.
Five of the 6 patients (83.3%) were diagnosed with stage
I EC. The results are summarized in Table 1.

On April 2, 2016, the patient underwent a total hysterectomy with bilateral salpingo-oophorectomy and periaortic
and pelvic lymphadenectomy. The uterus was reported to
contain minimally invasive mixed carcinoma (⬍50%),
consisting of low-grade endometrioid adenocarcinoma
(FIGO 1) admixed with a high-grade carcinoma with neuroendocrine differentiation. The fallopian tubes, ovaries,
and lymph nodes revealed no signs of metastases.

DISCUSSION
EC is the most common gynecologic malignancy in the
United States and affects 2.8% of women–slightly greater
than for other developed countries.28 –31 Abnormal uterine
bleeding, most often postmenopausal, is the presenting

Table 1.
Summary of PAEC Case Reports
Case

Age at
EA

Age at EC
Diagnosis

EA Procedure

Risk Factors

Symptoms

Stage

Diagnostic
Intervention

1

41

48

NovaSure N/A

HTN, obesity,
diabetes

Pain/mass

Stage I
FIGO 1

Endometrial biopsy
failed

2

33

50

Rollerball

Obesity

Irregular bleeding

Stage I
FIGO 3

RHS

3

56

61

EMR

Breast cancer

Pain

Stage III
mixed

None attempted

4

45

55

ThermaChoice

HTN, obesity,
diabetes

PMB

Stage I
FIGO 1

Endometrial biopsy
successful

5

42

40

Thermablate

Morbid obesity/
abnormal GTT

Bleeding & pain

Stage I
FIGO 1

RHS

6

49

54

NovaSure

Unopposed
estrogen

PMB

Stage I
Mixed

RHS

April-June 2017 Volume 21 Issue 2 e2017.00011
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spotting.32 An ultrasonography-guided reoperative hysteroscopic procedure revealed a sequestered nest of adenocarcinoma of the endometrium in the right cornua. A more
recent report by Argall et al39 contains 6 additional cases
of PAEC, but omits pertinent information regarding the
type of EA performed, the presence of EC at the time of
the procedure, and the nature of each subject’s presenting
symptoms.

symptom in 75 to 90% of subjects with EC.29 The known
risk factors for EC include obesity, hypertension, diabetes,
nulliparity, a history of breast cancer, and tamoxifen
use.33–35 The American Cancer Society predicts 60,050
new cases of EC in 2016 with 10,470 deaths attributable to
the disease.31,36 Between 1988 and 2012 the incidence of
EC in the United States increased by 18%—from 23.6 to
27.8 per 100,000 population29,31,36—a rise generally attributable to an aging population and increasing obesity
rates.28 –30 The average age at the time of diagnosis is 62
years with 75.8% occurring beyond the age of 55.29,31,36
Fortunately, most women with uterine cancers are diagnosed at an early stage with 67% confined to the uterine
corpus. Another 21% of ECs present with spread to regional organs and nodes while 8% involve distal metastases. The overall 5-year survival rate of EC is 81.7%.29,31,36

Our current report of 6 cases includes 4 instances of PAEC
after a GEA procedure and reflects the shift from REA to
GEA techniques. With the addition of these 6 cases, there
are now 35 cases that have been described in the English
literature, to our knowledge, 22 reported by AlHilli et al,24
6 by Argall et al,39 and 1 reported by the author (MW).32 Of
these 35 cases, only 24 contain sufficient material for
analysis24,32: 17 reported by AlHilli et al,24 1 in a previous
report by one of the authors (MW),32 and the 6 in this
report.

In 1993 Copperman et al37 described the first case of PAEC
in a 56-year-old woman who presented with postmenopausal bleeding 5 years after a resectoscopic EA. Her
evaluation permitted an endometrial biopsy revealing a
moderately well-differentiated (FIGO 2) adenocarcinoma.
In 1995 Margolis et al38 reported the earliest case of an
asymptomatic PAEC in a 58-year-old woman 3 years after
an REA. The report was disquieting, inasmuch as the stage
I FIGO grade 1 adenocarcinoma of the endometrium was
discovered only as an incidental finding after a procedure
for urinary stress incontinence. In 2011, AlHilli et al24 reviewed the English-language medical literature and identified 22 cases of PAEC, of which 17 were available for analysis. Fifteen of the subjects underwent REA whereas 2 had
undergone a GEA procedure: one had a prior ThermaChoice
(Gynecare Inc.) and another had a NovaSure EA (Hologic
Inc., Bedford MA). The mean age at the time of EC diagnosis was 54.4 years (95% CI 9.9; 49.7–59.2) with an
ablation-to-cancer interval varying from 6 months to 10
years. Thirteen of the cancers (76.5%) were detected at
stage I. Many of the subjects contained in AlHilli’s report
included women with significant EC risk factors, including
obesity (64.7%), diabetes (29.4%), and endometrial hyperplasia (41.2%). Of the 7 subjects with a preablation endometrial hyperplasia, 1 had simple hyperplasia, 3 had adenomatous (complex) hyperplasia, 2 had atypical
complex hyperplasia, and 1 was reported to have severe
hyperplasia. Arguably, many of these women would currently be considered inappropriate candidates for EA.

Since the early days of EA, surgeons have expressed
concerns that EA might affect the subsequent development of EC. Neuwirth et al25 assessed the incidence of EC
after EA in a population of 509 women with abnormal
perimenopausal bleeding and detected neither an increased nor reduced risk of EC in REA-treated women
compared to those in the U. S. SEER database.36 However,
Neuwirth investigated only REA-treated women at lowrisk for developing EC as subjects with a history of obesity, chronic anovulation, and diabetes were excluded.
Krogh et al40 reported 11 years’ follow-up data on 421
women who underwent transcervical resection of the endometrium (TRCE) from 1990 through 1996 and demonstrated a less-than-expected incidence of EC. However,
the study provided an insufficient surveillance period and
was composed of a group of women whose average age
was 56 ⫾ 6 years, well short of the mean age at which EC
typically presents. Finally, a more recent study by Singh et
al41 conducted in the United Kingdom included 1521
women who underwent various types of EA procedures
between 1994 and 2011 and noted that none of the
women in this retrospective observational study developed EC during the surveillance period. Their suggestion
that EA may even have a protective effect on the development of EC is unsupported by their data and the study’s
design. It appears, however, that the present literature
does not indicate an obvious deleterious effect on the
incidence of EC in an EA-treated population. However,
studies involving a large cohort of women undergoing
GEA techniques with a sufficient period of observation
have yet to be reported.

Since AlHilli’s review, one of the authors (MW) has reported a case of Stage I FIGO 1 PAEC in a 40-year-old
woman with no identifiable EC risk factors, who had
undergone a NovaSure EA 2 years earlier and presented
with severe cyclic pelvic pain associated with mild vaginal
April-June 2017 Volume 21 Issue 2 e2017.00011
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Other others have expressed concern that EA may affect
the clinical presentation of EC and have questioned what
the EA-to-EC interval, or latency period, might be.22–24,32
Reports18,24 have confirmed that EC may present with
new-onset vaginal bleeding, pelvic pain, or both, whereas
some cases may be entirely asymptomatic.18,24 In AlHilli’s
report,24 excluding 2 patients with EC at the time of the
ablation, the latency period averaged 3.9 years (6 months
to 10 years). Argall et al39 reported a similar interval in the
2 subjects who were diagnosed with EC 34 and 60 months
after EA. In our present series the EA–EC interval averaged
8.8 years and varied from 5 to 17 years; far lengthier than
has been observed. The combination of atypical presenting symptoms and the long latency period is likely to be
the source of a diagnostic challenge, particularly in the
postmenopausal woman who presents with acute pelvic
pain unaccompanied by vaginal bleeding many years after
the EA. In the absence of vaginal bleeding, PAEC may be
unintentionally excluded from the differential diagnosis—
particularly if the evaluating physician is not a gynecologist. Also troubling is that 3 of the 24 (12.5%) subjects
described to date were entirely asymptomatic at the time
of their cancer diagnosis, which raises concerns that these
patients may have eventually presented at a more advanced stage once they became symptomatic.

with the adroit maneuvering of a small-diameter hysteroscope. Only in case 4 was a traditional endometrial biopsy
successfully performed. These findings in our series may
reflect the fact that the ablation-to-cancer interval that we
observed is substantially longer than has been reported
and may have allowed additional scarring, contracture,
and sequestration to occur. Our observations support the
contention by Ahonkallio et al21 that traditional means of
evaluating the endometrial cavity are often obviated, or at
least challenging, in the postablation population. The limitations of sonography as a screening tool for postablation
EC has been addressed by Morelli et al42 who concludes
that, in the absence of studies that define a standardized
endometrial pattern after EA, transvaginal ultrasonography is of limited use in evaluating EA-treated women with
postmenopausal bleeding. They recommend that women
in whom the ultrasonogram indicates an echogenic or
echolucent collection within the uterus undergo hysteroscopic evaluation. However, they provide no guidance
regarding how to best address the complexities of endometrial sampling.
One of the authors (MW) has reported the use of sonographically guided hysteroscopic surgery for EA failures.43,44 This technique produces an excellent specimen
of sequestered areas of endometrium that require biopsy
and was the method used to diagnose a case reported by
one of the authors.32 However, most physicians will not
have access to this method, and hysterectomy may be the
only option available to most subjects who require adequate endometrial biopsy for evaluation of signs or symptoms of EC.

Another concern is that EA may alter the utility of diagnostic tests, such as endometrial biopsy or transvaginal
sonography. Although Argall et al39 indicated that “endometrial ablation artifact does not appear to hinder evaluation and treatment planning in the presence of endometrial cancer,” several surgeons have expressed concern
that EA-induced intrauterine synechiae and endometrial
sequestration may obscure and delay its diagnosis.22,23,17–21 This fear was underscored by Ahonkallio et
al21 who demonstrated that endometrial biopsy failed in
23% of women with a previous EA and was likely unreliable in many of the remaining subjects, given the sequestration of endometrium in the uterine cornua and elsewhere. AlHilli et al24 note that “that endometrial sampling
and investigation of abnormal uterine bleeding [after EA]
may be difficult to perform, yet are feasible and often of
high yield.” They note that “only in 2 cases (11.8%) was a
preoperative diagnosis with hysteroscopy or endometrial
biopsy not successful at presentation because of cervical
stenosis and intrauterine adhesions, respectively.” In contrast, the limitations of traditional endometrial biopsy are
clearly demonstrated in this report in which endometrial
biopsy was attempted in 5 of the 6 subjects. A biopsy
attempt in case 1 failed, and RHS was necessary in cases 2
and 5. In case 6 the diagnosis of EC was established only
April-June 2017 Volume 21 Issue 2 e2017.00011

The atypical presentation of PAEC and the challenges of
endometrial sampling and surveillance have caused some
authors to express concerns that EA may delay the diagnosis of EC, causing it to present at a more advanced
stage.17,18,24 However, must be larger prospective longterm studies to adequately understand the effect of EA on
the stage at which EC is detected. This longitudinal perspective is particularly relevant as we witness a large
cohort of women who have undergone GEA procedures
that may affect the endometrial cavity differently from
older REA techniques.

CONCLUSION
The United States28 –31,36 and other developed countries45,46 are presently witnessing an increasing incidence
of EC, reflecting both an aging population47 and rising
obesity rates.33,48,49
8
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ative evaluation should include a careful history, transvaginal sonography, hysteroscopically directed endometrial
biopsy, and a review of the patient’s risk factors for developing PAEC. In the lead author’s opinion (MW) the
importance of hysteroscopically directed endometrial biopsy cannot be overstated, as many significant lesions are
focal.51 Subjects with obesity, anovulatory bleeding, or a
history of breast cancer or tamoxifen use should be aware
of the increased risk for developing PAEC and the diagnostic challenges of this entity. In many instances, alternative treatment modalities must be offered and strongly
recommended for their AUB.

The United States is projected to experience a doubling in
the number of EC diagnoses by the year 2030 —to 122,000
cases per annum.28 –30 Such a doubling of the age-standardized incidence of EC has already been observed in
Korea in recent years.45,46 Simultaneously, the widespread
implementation of EA in the United States14,15,26 and other
industrialized countries within the past 20 years means
that a large population of EA-treated women, now entering their sixth and seventh decades of life, are at an
increasing age-related risk of developing EC. Several researcher-surgeons have suggested24,25,40,41 that EA does
not affect the stage at which EC presents. However, the
increasing use of this modality and the shift from NREA to
global EA requires larger prospective long-term studies to
adequately understand this question.
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